Niraparib treatment for patients with <i>BRCA</i>-mutated ovarian cancer: review of clinical data and therapeutic context-Reference-Cited by-同舟云学术

Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context

Published:2022-07 Issue:23 Volume:18 Page:2505-2536
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

González-Martín Antonio¹^ORCID,Matulonis Ursula A²^ORCID,Korach Jacob³^ORCID,Mirza Mansoor R⁴^ORCID,Moore Kathleen N⁵^ORCID,Wu Xiaohua⁶,York Whitney⁷,Gupta Divya⁸,Lechpammer Stanislav⁸,Monk Bradley J⁹^ORCID

Affiliation:

1. Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain & Program in Solid Tumors, Center for Applied Medical Research (CIMA), Madrid, 31008, Spain

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

3. Gynecologic Oncology Department, Chaim Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel Aviv University, 69978, Israel

4. Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, 2100, Denmark

5. Department of Gynecologic Oncology, Stephenson Cancer Center at the University of Oklahoma Health Science Center, Oklahoma City, OK 73104 & Sarah Cannon Research Institute, Nashville, TN 37203, USA

6. Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China,

7. GlaxoSmithKline, Upper Providence, PA 19426, USA

8. GlaxoSmithKline, Waltham, MA 02451, USA

9. HonorHealth Research Institute & Department of Obstetrics and Gynecology, University of Arizona, Creighton University, Phoenix, AZ 85258, USA

Abstract

We reviewed clinical data for niraparib monotherapy in BRCA-mutated ( BRCAm) epithelial ovarian cancer (OC), contextualizing results with data from other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib reduced the likelihood of progression or death by 60% as first-line maintenance therapy and by 73–78% in recurrent disease. In heavily pretreated OC, efficacy was greater in the BRCAm versus non- BRCAm cohort. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety and QoL evidence demonstrate niraparib maintenance monotherapy has a positive benefit:risk ratio in BRCAm OC. Niraparib significantly improved progression-free survival as first-line maintenance therapy in all patients with OC (i.e., of any biomarker status).

Funder

GSK

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-0206

Reference92 articles.

1. The forefront of ovarian cancer therapy: update on PARP inhibitors

2. Newly diagnosed ovarian cancer: Which first-line treatment?

3. The role of PARP in DNA repair and its therapeutic exploitation

4. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells

5. PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients;Cells;2023-09-13

2. A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers;Cancer Medicine;2023-08-30

3. DNA repair pathways in breast cancer: from mechanisms to clinical applications;Breast Cancer Research and Treatment;2023-06-08

4. Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy;Molecules;2022-07-25